Loudoun News

AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada

Based on regulatory agency feedback, the Company plans a registrational study that will evaluate hospitalization as the primary outcome measure, supported by multiple functional assessments as secondary outcome measures.

/C O R R E C T I O N — DCI Group/

In the news release, DCI Releases New Video Celebrating America 250 and the Firm's Commitment to Helping Citizens and Businesses Engage in the Democratic Process, issued 03-Jul-2026 by DCI Group…